1,750 research outputs found
Praeorbulina-like specimens" in sediments of the Northern Arabian Sea during the last glacial period
Date du colloque : 06/2009International audienc
Evolution of central pattern generators for the control of a five-link bipedal walking mechanism
Central pattern generators (CPGs), with a basis is neurophysiological
studies, are a type of neural network for the generation of rhythmic motion.
While CPGs are being increasingly used in robot control, most applications are
hand-tuned for a specific task and it is acknowledged in the field that generic
methods and design principles for creating individual networks for a given task
are lacking. This study presents an approach where the connectivity and
oscillatory parameters of a CPG network are determined by an evolutionary
algorithm with fitness evaluations in a realistic simulation with accurate
physics. We apply this technique to a five-link planar walking mechanism to
demonstrate its feasibility and performance. In addition, to see whether
results from simulation can be acceptably transferred to real robot hardware,
the best evolved CPG network is also tested on a real mechanism. Our results
also confirm that the biologically inspired CPG model is well suited for legged
locomotion, since a diverse manifestation of networks have been observed to
succeed in fitness simulations during evolution.Comment: 11 pages, 9 figures; substantial revision of content, organization,
and quantitative result
Clinical Determinants and Prognostic Implications of Renin and Aldosterone in Patients with Symptomatic Heart Failure
Aims Activation of the renin-angiotensin-aldosterone system plays an important role in the pathophysiology of heart failure (HF) and has been associated with poor prognosis. There are limited data on the associations of renin and aldosterone levels with clinical profiles, treatment response, and study outcomes in patients with HF. Methods and results We analysed 2,039 patients with available baseline renin and aldosterone levels in BIOSTAT-CHF (a systems BIOlogy study to Tailored Treatment in Chronic Heart Failure). The primary outcome was the composite of all-cause mortality or HF hospitalization. We also investigated changes in renin and aldosterone levels after administration of mineralocorticoid receptor antagonists (MRAs) in a subset of the EPHESUS trial and in an acute HF cohort (PORTO). In BIOSTAT-CHF study, median renin and aldosterone levels were 85.3 (percentile(25-75) = 28-247) mu IU/mL and 9.4 (percentile(25-75) = 4.4-19.8) ng/dL, respectively. Prior HF admission, lower blood pressure, sodium, poorer renal function, and MRA treatment were associated with higher renin and aldosterone. Higher renin was associated with an increased rate of the primary outcome [highest vs. lowest renin tertile: adjusted-HR (95% CI) = 1.47 (1.16-1.86), P = 0.002], whereas higher aldosterone was not [highest vs. lowest aldosterone tertile: adjusted-HR (95% CI) = 1.16 (0.93-1.44), P = 0.19]. Renin and/or aldosterone did not improve the BIOSTAT-CHF prognostic models. The rise in aldosterone with the use of MRAs was observed in EPHESUS and PORTO studies. Conclusions Circulating levels of renin and aldosterone were associated with both the disease severity and use of MRAs. By reflecting both the disease and its treatments, the prognostic discrimination of these biomarkers was poor. Our data suggest that the "point" measurement of renin and aldosterone in HF is of limited clinical utility
WONOEP appraisal: New genetic approaches to study epilepsy
New genetic investigation techniques, including next-generation sequencing, epigenetic profiling, cell lineage mapping, targeted genetic manipulation of specific neuronal cell types, stem cell reprogramming, and optogenetic manipulations within epileptic networks are progressively unraveling the mysteries of epileptogenesis and ictogenesis. These techniques have opened new avenues to discover the molecular basis of epileptogenesis and to study the physiologic effects of mutations in epilepsy associated genes on a multilayer level, from cells to circuits. This manuscript reviews recently published applications of these new genetic technologies in the study of epilepsy, as well as work presented by the authors at the genetic session of the XII Workshop on the Neurobiology of Epilepsy (WONOEP 2013) in Quebec, Canada. Next-generation sequencing is providing investigators with an unbiased means to assess the molecular causes of sporadic forms of epilepsy and has revealed the complexity and genetic heterogeneity of sporadic epilepsy disorders. To assess the functional impact of mutations in these newly identified genes on specific neuronal cell types during brain development, new modeling strategies in animals, including conditional genetics in mice and in utero knock-down approaches, are enabling functional validation with exquisite cell-type and temporal specificity. In addition, optogenetics, using cell-typeâspecific Cre recombinase driver lines, is enabling investigators to dissect networks involved in epilepsy. In addition, genetically encoded cell-type labeling is providing new means to assess the role of the nonneuronal components of epileptic networks such as glial cells. Furthermore, beyond its role in revealing coding variants involved in epileptogenesis, next-generation sequencing can be used to assess the epigenetic modifications that lead to sustained network hyperexcitability in epilepsy, including methylation changes in gene promoters and noncoding ribonucleic acid (RNA) involved in modifying gene expression following seizures. In addition, genetically based bioluminescent reporters are providing new opportunities to assess neuronal activity and neurotransmitter levels both in vitro and in vivo in the context of epilepsy. Finally, genetically rederived neurons generated from patient induced pluripotent stem cells and genetically modified zebrafish have become high-throughput means to investigate disease mechanisms and potential new therapies. Genetics has changed the field of epilepsy research considerably, and is paving the way for better diagnosis and therapies for patients with epilepsy
WONOEP appraisal: New genetic approaches to study epilepsy
New genetic investigation techniques, including next-generation sequencing, epigenetic profiling, cell lineage mapping, targeted genetic manipulation of specific neuronal cell types, stem cell reprogramming, and optogenetic manipulations within epileptic networks are progressively unraveling the mysteries of epileptogenesis and ictogenesis. These techniques have opened new avenues to discover the molecular basis of epileptogenesis and to study the physiologic effects of mutations in epilepsy associated genes on a multilayer level, from cells to circuits. This manuscript reviews recently published applications of these new genetic technologies in the study of epilepsy, as well as work presented by the authors at the genetic session of the XII Workshop on the Neurobiology of Epilepsy (WONOEP 2013) in Quebec, Canada. Next-generation sequencing is providing investigators with an unbiased means to assess the molecular causes of sporadic forms of epilepsy and has revealed the complexity and genetic heterogeneity of sporadic epilepsy disorders. To assess the functional impact of mutations in these newly identified genes on specific neuronal cell types during brain development, new modeling strategies in animals, including conditional genetics in mice and in utero knock-down approaches, are enabling functional validation with exquisite cell-type and temporal specificity. In addition, optogenetics, using cell-typeâspecific Cre recombinase driver lines, is enabling investigators to dissect networks involved in epilepsy. In addition, genetically encoded cell-type labeling is providing new means to assess the role of the nonneuronal components of epileptic networks such as glial cells. Furthermore, beyond its role in revealing coding variants involved in epileptogenesis, next-generation sequencing can be used to assess the epigenetic modifications that lead to sustained network hyperexcitability in epilepsy, including methylation changes in gene promoters and noncoding ribonucleic acid (RNA) involved in modifying gene expression following seizures. In addition, genetically based bioluminescent reporters are providing new opportunities to assess neuronal activity and neurotransmitter levels both in vitro and in vivo in the context of epilepsy. Finally, genetically rederived neurons generated from patient induced pluripotent stem cells and genetically modified zebrafish have become high-throughput means to investigate disease mechanisms and potential new therapies. Genetics has changed the field of epilepsy research considerably, and is paving the way for better diagnosis and therapies for patients with epilepsy
Reduction In body weight is an independent risk factor for mortality in chronic heart failure. Insights from GISSI-HF and Val-HeFT trials
n/
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163454/2/ejhf1909_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163454/1/ejhf1909.pd
Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice
Cardiotrophin 1 (CT-1), an interleukin 6 family member, promotes fibrosis and arterial stiffness. We hypothesized
that the absence of CT-1 influences arterial fibrosis and stiffness, senescence, and life span. In senescent 29-month-
old mice, vascular function was analyzed by echotracking device. Arterial histomorphology, senescence, metabolic,
inflammatory, and oxidative stress parameters were measured by immunohistochemistry, reverse transcription polymerase
chain reaction, Western blot, and ELISA. Survival rate of wild-type and CT-1ânull mice was studied. Vascular smooth
muscle cells were treated with CT-1 (10
â9
mol/L) for 15 days to analyze senescence. The wall stress-incremental elastic
modulus curve of old CT-1ânull mice was shifted rightward as compared with wild-type mice, indicating decreased
arterial stiffness. Media thickness and wall fibrosis were lower in CT-1ânull mice. CT-1ânull mice showed decreased
levels of inflammatory, apoptotic, and senescence pathways, whereas telomere-linked proteins, DNA repair proteins,
and antioxidant enzyme activities were increased. CT-1ânull mice displayed a 5-month increased median longevity
compared with wild-type mice. In vascular smooth muscle cells, chronic CT-1 stimulation upregulated apoptotic and
senescence markers and downregulated telomere-linked proteins. The absence of CT-1 is associated with decreased
arterial fibrosis, stiffness, and senescence and increased longevity in mice likely through downregulating apoptotic,
senescence, and inflammatory pathways. CT-1 may be a major regulator of arterial stiffness with a major impact on the
aging proces
- âŠ